Drug delivery technologies have enabled the development of many pharmaceutical
products that improve patient health by enhancing the delivery of a therapeutic to its target …

Pioneer factors are transcription factors with the unique ability to initiate opening of closed
chromatin. The stability of cell identity relies on robust mechanisms that maintain the …

Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable …

In situ tissue regeneration harnesses the body's regenerative potential to control cell
functions for tissue repair. The design of biomaterials for in situ tissue engineering requires …

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

In spite of the considerable achievements in the field of regenerative medicine in the past
several decades, osteochondral defect regeneration remains a challenging issue among …

Over the past 20 years, and particularly in the last decade, significant developmental
milestones have driven basic, translational, and clinical advances in the field of stem cell …

Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset
of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their …

Normal wound healing is a dynamic and complex multiple phase process involving
coordinated interactions between growth factors, cytokines, chemokines, and various cells …

Induced pluripotent stem cell (iPSC)-based disease modelling and the cell replacement
therapy approach have proven to be very powerful and instrumental in biomedical research …